Home
News
Create
Screeners
Insights
Vivo Bio Tech
33.
70
+0.88
(+2.68%)
Market Cap
₹71.50 Cr
PE Ratio
8.46
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+2.68%
1M
-8.94%
6M
-3.66%
1Y
-12.10%
5Y
-18.50%
View Company Insights
Latest news about Vivo Bio Tech
Vivo Bio Tech Secures ₹10.75 Crore Pre-Clinical Testing Contract for Novel Molecule
Aug 20, 2025
Vivo Bio Tech Limited has secured a pre-clinical testing contract worth ₹10.75 crores with a leading Indian pharmaceutical and agro-chemical company. The two-year contract involves comprehensive pre-clinical safety and regulatory studies for a novel molecule, including toxicity, mutagenicity, ecotoxicology studies, and analytical services. The studies will be conducted under Section 9(3) requirements for submission to the Central Insecticides Board & Registration Committee (CIBRC). This contract positions Vivo Bio Tech among top Contract Research Organizations in India, demonstrating its capability to deliver integrated pre-clinical solutions meeting national and international regulatory standards.
Vivo Bio Tech Reports Strong Q1 FY2026 Performance with 29.66% Revenue Growth
Aug 14, 2025
Vivo Bio Tech Shareholders Approve Increase in Authorized Share Capital
Aug 04, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation